EUVIMEDEUVIMED entdecken
Crossref

Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML

Nada Alaa El-Deen, RosaAnna DeFilippis, Amal Kamal Abdel-Aziz, Sandra N Milik, Suhana Patel, Muhammad I Ismail, Omar Khaled, Tarek Erfan Ahmed, Ayatullah Gamal Abdelfattah, Eslam M H Ali, Maiy Y Gaballah, Martin J McPhillie und 6 weitere

Archiv der Pharmazie · 2025

DOI: 10.1002/ardp.70002 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Archiv der Pharmazie, 2025. Verfasst von Nada Alaa El-Deen und 17 weiteren Autor:innen. Beteiligte Einrichtung: Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt. Hauptthemen laut MEDLINE: fms-Like Tyrosine Kinase 3, Benzimidazoles, Leukemia, Myeloid, Acute, Protein Kinase Inhibitors. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 77 Literaturangaben. Gefördert von: The authors received no specific funding for this study..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Acute myeloid leukemia (AML) is an aggressive hematological malignancy with poor survival rates in adults, posing a significant economic burden. FMS‐like tyrosine kinase 3 (FLT3) mutations are linked to poor prognosis in AML and resistance to clinically approved FLT3 inhibitors. Previously, we reported a novel benzimidazole‐based FLT3 inhibitor, 4ACP, with nanomolar activities against FLT3‐ITD and FLT3‐TKD mutants, showing selective cytotoxicity against FLT3‐ITD + AML cell lines. In this study, we synthesized 31 derivatives by modifying the 4‐acetamidophenyl group and varying substituents at N 1‐phenyl and C2 positions. We identified compound 21l (3‐acetamidophenyl) as the most potent derivative (FLT3‐TKD(D835Y) IC 50 = 1.47 nM). Linking 21l to a solvent‐accessible group yielded compound 22b , which exhibited a sub‐nanomolar activity against FLT‐TKD(D835Y) mutant with an IC 50 value of 0.48 nM. Compound 22b showed preferential antiproliferative activities against MOLM‐14, MV4‐11, MOLM‐14‐D835Y, and MOLM‐14‐F691L AML cell lines with IC 50 values of 16.1, 10.5, 26.5, and 160.3 nM, respectively. 22b induced dose‐dependent inhibition of FLT3, ERK, STAT5, and S6 phosphorylation, G0/G1 cell‐cycle arrest, and apoptotic cell death at low nanomolar concentrations in MOLM‐14 and MOLM‐14‐D835Y cells. It was more selective for FLT3‐dependent cell lines, showing about 80‐fold selectivity toward FLT3‐TKD(D835Y) over KIT, indicating relative safety and lower myelosuppression potential. The molecular dynamics study of 4ACP and 22b was conducted to explain the significant changes in activity resulting from subtle structural alterations. Altogether, these findings establish 22b as a potent mutant FLT3 inhibitor, warranting further investigation and optimization to target resistant AML.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

fms-Like Tyrosine Kinase 3BenzimidazolesLeukemia, Myeloid, AcuteProtein Kinase InhibitorsAntineoplastic AgentsHumansStructure-Activity RelationshipCell ProliferationMolecular Dynamics SimulationMutationMolecular StructureDose-Response Relationship, DrugCell Line, TumorDrug Screening Assays, AntitumorApoptosis

Stichwörter der Autor:innen

acute myeloid leukemiabenzimidazolekinase inhibitormolecular dynamicsmutant FLT3

Substanzen

fms-Like Tyrosine Kinase 3BenzimidazolesProtein Kinase InhibitorsFLT3 protein, humanAntineoplastic Agents

Autor:innen und Institutionen

  • Pharmaceutical Chemistry Department, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt.
  • Division of Hematology/Oncology, University of California, San Francisco, California, USA.
  • Department of Pharmacology and Toxicology, Faculty of Pharmacy, Ain Shams University, Abbassia, Cairo, Egypt.
  • Department of Experimental Oncology, IEO, European Institute of Oncology IRCCS, Milan, Italy.
  • School of Chemistry, University of Leeds, Leeds, UK.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, The British University in Egypt, Al-Sherouk City, Cairo, Egypt.

Förderung

  • The authors received no specific funding for this study.

Zitieren

APA

El-Deen, N. A., DeFilippis, R., Abdel-Aziz, A. K., Milik, S. N., Patel, S., Ismail, M. I., Khaled, O., Ahmed, T. E., Abdelfattah, A. G., Ali, E. M. H., Gaballah, M. Y., McPhillie, M. J., Abouzid, K. A. M., Serya, R. A. T., Henary, M., Minucci, S., Shah, N. P., & Dokla, E. M. E. (2025). Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML. Archiv der Pharmazie. https://doi.org/10.1002/ardp.70002

Vancouver

El-Deen NA, DeFilippis R, Abdel-Aziz AK, Milik SN, Patel S, Ismail MI, et al. Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML. Archiv der Pharmazie. 2025. doi:10.1002/ardp.70002

BibTeX
@article{ElDeen2025,
  author = {El-Deen, Nada Alaa and DeFilippis, RosaAnna and Abdel-Aziz, Amal Kamal and Milik, Sandra N and Patel, Suhana and Ismail, Muhammad I and Khaled, Omar and Ahmed, Tarek Erfan and Abdelfattah, Ayatullah Gamal and Ali, Eslam M H and Gaballah, Maiy Y and McPhillie, Martin J and Abouzid, Khaled A M and Serya, Rabah A T and Henary, Maged and Minucci, Saverio and Shah, Neil P and Dokla, Eman M E},
  title = {Structural Optimization and MD Simulation Study of Benzimidazole Derivatives as Potent Mutant FLT3 Kinase Inhibitors Targeting AML},
  journal = {Archiv der Pharmazie},
  year = {2025},
  doi = {10.1002/ardp.70002}
}
Kostenlos starten →